Bio Medica Laboratories Ltd
Incorporated in August 2015,
Bio Medica Laboratories Ltd
specialises in manufacturing
pharmaceutical parenteral
formulations, producing a
wide range of ethical drugs,
generic drugs, and over-the
-counter (OTC) medications[1]
- Market Cap ₹ 196 Cr.
- Current Price ₹ 156
- High / Low ₹ 181 / 102
- Stock P/E 16.8
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 44.6 %
- ROE 56.8 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 70.3%
Cons
- Debtor days have increased from 60.5 to 86.4 days.
- Working capital days have increased from 197 days to 329 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 16 | 15 | 38 | 38 | |
| 15 | 10 | 23 | 20 | |
| Operating Profit | 2 | 6 | 15 | 18 |
| OPM % | 10% | 37% | 40% | 48% |
| 0 | 0 | 0 | 0 | |
| Interest | 1 | 1 | 1 | 2 |
| Depreciation | 0 | 1 | 1 | 1 |
| Profit before tax | 0 | 4 | 13 | 16 |
| Tax % | 27% | 32% | 25% | 26% |
| 0 | 2 | 10 | 12 | |
| EPS in Rs | 0.36 | 2.72 | 10.66 | 12.71 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 228% |
| TTM: | 19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 70% |
| Last Year: | 57% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 9 | 9 |
| Reserves | 2 | 5 | 6 | 17 |
| 10 | 10 | 15 | 23 | |
| 6 | 4 | 9 | 8 | |
| Total Liabilities | 18 | 20 | 39 | 57 |
| 8 | 9 | 8 | 7 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| 9 | 11 | 31 | 51 | |
| Total Assets | 18 | 20 | 39 | 57 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 2 | 2 | -5 | -6 | |
| -2 | -2 | 0 | -0 | |
| -2 | -0 | 5 | 6 | |
| Net Cash Flow | -2 | 0 | 0 | 0 |
| Free Cash Flow | 1 | 0 | -5 | -6 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 147% | 31% | -7% | -9% |
Ratios
Standalone / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 92 | 56 | 39 | 86 |
| Inventory Days | 309 | 808 | 678 | 1,357 |
| Days Payable | 361 | 223 | 160 | 105 |
| Cash Conversion Cycle | 39 | 641 | 557 | 1,338 |
| Working Capital Days | -25 | 95 | 166 | 329 |
| ROCE % | 34% | 64% | 45% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Ampoule Capacity Utilization % |
|
||
| Ampoule Installed Capacity Nos. per Annum |
|||
| Ampoule Production Volume Nos. per Annum |
|||
| New Product Revenue Share % of Revenue from Operations |
|||
| Top 5 Customer Revenue Concentration % of Revenue from Operations |
|||
| Vial Capacity Utilization % |
|||
| Vial Installed Capacity Nos. per Annum |
|||
| Vial Production Volume Nos. per Annum |
|||
Extracted by Screener AI
Documents
Announcements
-
Structural Digital Database
- Submitted SDD compliance certificate for quarter ended 30 September 2026, confirming 5 events captured.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended September 30, 2026.
-
Shareholders meeting
- 11th AGM voting results: four resolutions passed, including FY26 adoption, Mukesh Mehta reappointment, and 49% FPI/FII limit increase.
-
General Updates
- AGM on 28 Sep 2026 approved accounts, director reappointment, secretarial auditor, and FPI/FII limit to 49%.
-
Shareholders meeting
- Bio Medica held 11th AGM on 28 Sep 2026; approved FY26 accounts, reappointed director, and raised FPI/FII limit to 49%.
Business Profile:[1]
Bio Medica Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations, primarily generic injectable drugs.
The company manufactures liquid injections
and dry powder injections for both human
and veterinary use under a B2B/contract manufacturing model. Products are marketed
by client companies while Bio Medica acts
as the manufacturer.